ACT-AD Presents at FDA Public Meeting on the Fifth Reauthorization of PDUFA

ACT-AD Chairman Daniel Perry presented on a patient panel during an FDA public meeting on the fifth reauthorization of the Prescription Drug User Fee Act (PDUFA). In his remarks, Mr. Perry emphasized the need for FDA to have the ability to play a more significant role in encouraging the development of new therapies for diseases like Alzheimer’s by increasing their capacity to qualify biomarkers and other endpoints for use in development, and to continue assessing the benefits and risks of new therapies post-approval so as not to delay treatments for patients who may benefit from them.
View Transcript

File Attachments